Yushin Company (6482) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
21 Jul, 2026Executive summary
FY2025 net sales reached ¥26,126 million, up 10.6% year-over-year, driven by strong custom-ordered equipment and robot sales, especially in Japan and medical-related projects, despite global economic uncertainty and rising material costs.
Operating profit increased 6.1% year-over-year to ¥2,586 million, while ordinary profit declined 2.0% to ¥2,535 million due to foreign exchange losses.
Profit attributable to owners was flat at ¥1,692 million.
FY2026 forecasts anticipate a decline in net sales and operating profit due to uncertain capital investment demand in Europe and the US, though automation demand remains robust.
Strategic focus on strengthening human capital, global sales, and product capabilities, with ongoing investment in R&D and sustainability initiatives.
Financial highlights
FY2025 net sales: ¥26,126 million, up 10.6% year-over-year.
Operating profit: ¥2,586 million, up 6.1% year-over-year.
Gross profit: ¥10,767 million, gross profit margin: 41.2% in FY2025.
Profit attributable to owners: ¥1,692 million, flat year-over-year.
FY2026 forecast: net sales ¥25,000 million (down 4.3%), operating profit ¥2,200 million (down 14.9%), ordinary profit ¥2,200 million (down 13.2%), profit attributable to owners ¥1,500 million (down 11.4%).
Outlook and guidance
Medium- to long-term automation demand expected to continue, but near-term sales to decrease due to weak capital investment in Europe and the US.
Robot sales projected to rise 10.3% year-over-year in FY2026, while custom-ordered equipment sales expected to drop 41.8%.
Continued proactive investment in human resources and production efficiency initiatives.
Company expects continued global uncertainty but plans to invest in human resources and automation to drive future growth.
Latest events from Yushin Company
- Sales and operating profit surged, but ordinary profit fell on forex losses; outlook steady.6482
Q2 202521 Jul 2026 - Sales surged 19.7% year-over-year, but profit margins narrowed on higher costs.6482
Q1 202521 Jul 2026 - Net sales rose 14.5% year-over-year, with robust growth in Japan and Europe.6482
Q3 202521 Jul 2026 - Operating profit rose despite lower sales, with Asia growth offset by Europe weakness.6482
Q1 202621 Jul 2026 - Profits fell sharply on weak medical equipment sales, but dividends and buybacks are maintained.6482
Q2 202621 Jul 2026 - Profits and sales fell sharply in FY2026, but a strong rebound is forecast for FY2027.6482
Q4 202621 Jul 2026 - Profits and sales fell sharply year-over-year, with Europe showing the largest decline.6482
Q3 202621 Jul 2026